Patterns of recurrence and outcomes in patients with luminal breast cancer: a retrospective study

Background: Patients with luminal breast cancer have better prognosis and survival rates compared to patients with non-luminal breast cancers, such as basal-like and HER-2 subtypes, owing to the added benefits of adjuvant endocrine therapy. However, local relapses and distant metastasis still frequently occur. In recent years, more studies on breast cancer relapse and metastasis have focused on non-luminal breast cancers despite there being more number of cases of luminal breast cancer. Materials and Methods: In this study, the authors included 387 breast cancer patients with recurrence and metastasis who were treated in their hospital between January 2001 and June 2011, and divided them into luminal and non-luminal groups. The differences in clinical and pathological characteristics, survival rates, and prognostic features after follow-up treatment were retrospectively analyzed in the two groups. Results: The authors found there was a higher proportion of local recurrence and single bone metastasis in luminal group than in the non-luminal group. The risk of recurrence and metastasis in the luminal group two to five years and after five years post-operation continued to be stable, but the risk in the non-luminal group significantly decreased after two years. Conclusions: Luminal breast cancer patients with recurrence or/and metastasis had better prognosis after reasonable treatment. These results are of potential clinical relevance, especially for clinical prognosis monitoring and targeted therapy interventions in patients with luminal breast cancer.

Luminal breast cancer; Recurrence pattern; Prognosis.

[1] Karlsson P., Cole B.F., Chua B.H., Price K.N., Lindtner J., Collins J.P., et al.: “Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report”. Ann. Oncol., 2012, 23, 2852.

[2] Katz A., Buchholz T.A., Thames H., Smith C.D., McNeese M.D., Theriault R., et al.: “Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50, 397.

[3] Quan M.L., Osman F., McCready D., Fernandes K., Sutradhar R., Paszat L.: “Postmastectomy radiation and recurrence patterns in breast cancer patients younger than age 35 years: a population-based cohort”. Ann. Surg. Oncol., 2014, 21, 395.

[4] Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al.: “Repeated observation of breast tumor subtypes in independent gene expression data sets”. Proc. Natl. Acad. Sci. USA., 2003, 100, 8418.

[5] Minicozzi P., Bella F., Toss A., Giacomin A., Fusco M., Zarcone M., et al.: “Relative anddisease-free survival for breast cancer in relation to subtype: a population-based study”. J. Cancer. Res. Clin. Oncol., 2013, 139, 1569.

[6] Boyle P.: “Triple-negative breast cancer: epidemiological considerations and recommendations. Triple-negative breast cancer: epidemiological considerations and recommendations”. Ann. Oncol., 2012, 23, vi7.

[7] Brady-West D.C., McGrowder D.A.: “Triple negative breast cancer: therapeutic and prognostic implications”. Asian Pac. J. Cancer Prev., 2011, 12, 2139.

[8] Hammond M.E., Hayes D.F., Wolff A.C., Mangu P.B., Temin S.: “American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer”. J. Oncol. Pract., 2010, 6, 195.

[9] Kamil M., Yusuf N., Khalid I., Islam R., Biswas M., Hashim H.: “Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia”. Ceylon Med. J., 2010, 55, 9.

[10] Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., et al.: “Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer”. Ann. Oncol., 2013, 24, 2206.

[11] Early Breast Cancer Trialists’ Collaborative Group.: “Tamoxifen for early breast cancer: an overview of the randomised trials”. Lancet, 1998, 351, 1451.

[12] Borner M., Bacchi M., Goldhirsch A., Greiner R., Harder F., Castiglione M., et al.: “First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research”. J. Clin. Oncol., 1994, 12, 2071.

[13] Kawai M., Malone K.E., Tang M.T., Li C.I.: “Height, body mass index (BMI), BMI change and the risk of estrogen receptor-positive, HER2-positive and triple-negative breast cancer among women ages 20 to 44 years”. Cancer, 2014, 120, 1548.

[14] Colzani E., Johansson A.L., Liljegren A., Foukakis T., Clements M., Adolfsson J., et al.: “Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics”. Br. J. Cancer, 2014, 110, 1378.

[15] Khadakban D., Gorasia-Khadakban T., Vijaykumar D.K., Pavithran K., Anupama R.: “Factors associated with better survival after surgery in metastatic breast cancer patients”. Indian J. Surg. Oncol., 2013, 4, 52.

[16] Theriault R.L., Carlson R.W., Allred C., Anderson B.O., Burstein H.J., Edge S.B., et al.: “Breast cancer, version 3.2013: featured updates to the NCCN guidelines”. J. Natl. Compr. Canc. Netw., 2013, 11, 753; quiz 761.

[17] Fedele P., Calvani N., Marino A., Orlando L., Schiavone P., Quaranta A., et al.: “Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going”? Crit. Rev. Oncol. Hematol., 2012, 84, 243.

[18] Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al.: “Triple-negative breast cancer: clinical features and patterns of recurrence”. Clin. Cancer Res., 2007, 13, 4429.

[19] Engel J., Eckel R., Aydemir U., Aydemir S., Kerr J., Schlesinger- Raab A., et al.: “Determinants and prognoses of locoregional and distant progression in breast cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2003, 55, 1186.

[20] Willner J., Kiricuta I.C., Kölbl O.: “Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis”. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37, 853.

[21] Demicheli R., Bonadonna G., Hrushesky W.J., Retsky M.W., Valagussa P.: “Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour”. Breast Cancer Res., 2004, 6, R689.

[22] Aebi S., Gelber S., Anderson S.J., Láng I., Robidoux A., Martín M., et al.: “Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial”. Lancet Oncol., 2014, 15, 156.

[23] Clemons M., Danson S., Hamilton T., Goss P.: “Locoregionally recurrent breast cancer: incidence, risk factors and survival”. Cancer Treat. Rev., 2001, 27, 67.

[24] Colleoni M., O’Neill A., Goldhirsch A., Gelber R.D., Bonetti M., Thürlimann B., et al.: “Identifying breast cancer patients at high risk for bone metastases”. J. Clin. Oncol., 2000, 18, 3925.

[25] Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U.: “Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer”. J. Clin. Oncol., 1996, 14, 2197.

[26] Ren Z., Li Y., Hameed O., Siegal G.P., Wei S.: “Prognostic factors in patients with metastatic breast cancer at the time of diagnosis”. Pathol. Res. Pract., 2014, 210, 301.

[27] Lobbezoo D.J., van Kampen R.J., Voogd A.C., Dercksen M.W., van den Berkmortel F., Smilde T.J., et al.: “Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome”. Breast Cancer Res. Treat., 2013, 141, 507.